Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design
about
Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazoleOxidative status interactome map: towards novel approaches in experiment planning, data analysis, diagnostics and therapy.A whole genome SNP genotyping by DNA microarray and candidate gene association study for kidney stone diseaseMetabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type IInvolvement of ionizable groups in catalysis of human liver glycolate oxidase.Another look at the interaction between mitochondrial cytochrome c and flavocytochrome b (2).An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.Recombinant production of eight human cytosolic aminotransferases and assessment of their potential involvement in glyoxylate metabolism.Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria.HAO1 tetramer oxidizes glycolate to glyoxylateConversion of glyoxylate to oxalatePlant and animal glycolate oxidases have a common eukaryotic ancestor and convergently duplicated to evolve long-chain 2-hydroxy acid oxidases.Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria.
P2860
Q24649940-C800DBDB-37DF-4007-991A-2EF98A1C1D92Q30630953-992DCBEC-7E5F-4128-8CE1-2D04BFE34A07Q33652263-7BDAA4E6-236F-4FE5-9935-55DDF37F332EQ35849447-BE990755-38CF-4959-9C97-1C16FDA5FF2FQ36190922-158645E4-36CB-4DFE-84B0-9D5362C3C210Q36951260-E67EBFEC-E6DF-4AAF-A242-3A6A34E5CD8FQ37431488-0F165C0F-5C90-4F1E-9284-0F7C868FA22EQ37866680-C972740C-2BA3-42B6-97AB-E111FA619F73Q39586687-34C8CBC5-EE47-4D57-B472-C15EDA80E698Q40015456-14550AC9-6455-452D-9AA2-2603A26CD41BQ43098007-0DAC63D0-B7EC-48C5-81A5-3FE190DA8773Q45958835-9ADCC2B1-8844-4535-B0AA-F80C747D9995Q48018129-E01D5C89-8E7F-4068-862A-AFCBF4CBA661Q50295149-73CA87C6-8B6F-4A09-9B7E-4E45E4DE4A20Q50295150-9B8E2C0A-A7B9-48F2-93EB-5145E32DD886Q50464082-6E5077B4-4C9E-4D29-B636-FF18C902D0B2Q53036734-521669DF-2986-40A9-9227-D14B33AA592B
P2860
Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Active site and loop 4 movemen ...... te specificity and drug design
@ast
Active site and loop 4 movemen ...... te specificity and drug design
@en
Active site and loop 4 movemen ...... te specificity and drug design
@en-gb
Active site and loop 4 movemen ...... te specificity and drug design
@nl
type
label
Active site and loop 4 movemen ...... te specificity and drug design
@ast
Active site and loop 4 movemen ...... te specificity and drug design
@en
Active site and loop 4 movemen ...... te specificity and drug design
@en-gb
Active site and loop 4 movemen ...... te specificity and drug design
@nl
altLabel
Active Site and Loop 4 Movemen ...... Specificity and Drug Design †
@en
prefLabel
Active site and loop 4 movemen ...... te specificity and drug design
@ast
Active site and loop 4 movemen ...... te specificity and drug design
@en
Active site and loop 4 movemen ...... te specificity and drug design
@en-gb
Active site and loop 4 movemen ...... te specificity and drug design
@nl
P2860
P356
P1433
P1476
Active site and loop 4 movemen ...... te specificity and drug design
@en
P2093
Michael S Murray
W Todd Lowther
P2860
P304
P356
10.1021/BI701710R
P407
P577
2008-01-24T00:00:00Z